Treatment and Natural History Study of Lymphomatoid Granulomatosis
Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid, Non-Hodgkins Lymphoma
About this trial
This is an interventional treatment trial for Lymphomatoid Granulomatosis focused on measuring Epstein-Barr Virus, Lymphoproliferative Disorder, Viral, Immunosuppression, Lymphoma
Eligibility Criteria
INCLUSION CRITERIA: Patients must have a tissue-diagnosis of grade 1, 2 and/or 3 LYG (or a diagnosis consistent with LYG) confirmed by the Laboratory of Pathology, NCI. Final histopathologic classification and pathologic grade will be determined by Stephania Pittaluga, M.D. or her designee. Patients with any stage of disease will be eligible. Previously untreated and treated patients are eligible. Patients age 12 or older will be eligible. EXCLUSION CRITERIA: Patients with a history of coronary artery disease with angina pectoris, or a history of congestive heart failure will not be eligible to receive. DA-Epoch-R chemotherapy. Patients with significant renal (Cr. greater than 1.5 mg/dl or creatinine less than 40 cc/min) or hepatic (bilirubin greater than 2.5 u) dysfunction not due to tumor involvement will not be eligible to receive DA-EPOCH-R chemotherapy. Informed consent must be obtained. Patients who in the opinion of the principle investigator are poor psychiatric or medical risk are not eligible. Patients who received > 450 mg/m2 doxorubicin and have a cardiac ejection fraction on echocardiogram less than or equal to 40% on protocol entry are not eligible to received DA-EPOCH-R. Patients with prior hepatitis B exposure may be included in the study provided that they have HBV DNA levels below the World Health Organization s cutoff of 100 IU/mL prior to starting therapy.
Sites / Locations
- National Institutes of Health Clinical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
1
2
Interferon starting at 7.5 million Units subQ 3 times a week and increasing on the designated schedule, as tolerated. Patients continue taking interferon for 1 year beyond CR. Patients who progress may crossover to receive EPOCH-R.
EPOCH-R every 3 weeks for up to 6 cycles, based on response.